Intellia adopts bylaw amendments adding shareholder cure provision and exclusive federal forum clause

Intellia Therapeutics, Inc.

Added provision allowing shareholders to cure facially apparent deficiencies in timely nomination or proposal notices.
Designated U.S. federal district courts as exclusive forum for claims under Securities Act of 1933 and Exchange Act of 1934, unless company consents otherwise.
Amendments effective April 7, 2026, adopted by Board on recommendation of nominating and corporate governance committee.
Fourth Amended and Restated Bylaws filed as Exhibit 3.1 to this Form 8-K.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Intellia Therapeutics, Inc.: Board adopted Fourth Amended and Restated By-laws adding a cure period for deficiencies in shareholder notices and designating federal district courts as exclusive forum for federal securities law actions (effective 2026-04-07).

Change: bylaw amendment
Effective: 2026-04-07

Exact text from the filing

On April 7, 2026, based on the recommendation of the nominating and corporate governance committee of the board of directors (the “Board”) of Intellia Therapeutics, Inc. (the “Company”), the Board adopted amendments to the Company’s Third Amended and Restated By-laws. Under the Fourth Amended and Restated By-laws, which are effective April 7, 2026 (the “Amended By-laws”), the Company added a provision allowing shareholders to cure any facially apparent deficiencies in a shareholder’s timely notice of a nomination or proposal, and requiring the Company to notify the shareholder of any facially apparent deficiencies in a timely notice. In addition, the Amended By-laws designate the federal district courts of the United States as the exclusive forum for resolving any complaint that asserts a cause of action arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Com

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-151300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.